Radio-pharma biotech Telix is building on the success – and the cashflow – from its nuclear-guided prostate cancer tool to aim for new cancers, and new treatments.
Christian Behrenbruch was outraged. That’s what started it all. The then 26-year-old PhD candidate from Melbourne was at a routine lab meeting at Oxford when it was mentioned that the lab was dropping a bunch of patents it owned.
